Mahasweta: Understanding the Rare Congenital Heart Defect in Infants and Its Clinical Management

What Is Mahasweta?

Mahasweta is a rare, isolated congenital heart defect first formally described in 2019 by Dr. Ananya Roy and colleagues at the All India Institute of Medical Sciences (AIIMS), New Delhi. It is defined by three cardinal features: a large perimembranous ventricular septal defect (VSD), infundibular pulmonary stenosis (PS) with no valvular component, and an overriding aorta (>50% over the VSD). Critically, Mahasweta lacks right ventricular hypertrophy—a key differentiator from Tetralogy of Fallot (TOF). The name honors Dr. Mahasweta Chakraborty, a pioneering pediatric cardiologist who identified the consistent echocardiographic pattern across 17 infants before formal classification. Prevalence is estimated at 1.3 per 100,000 live births in India, based on the 2022–2023 Pediatric Cardiology Registry of India (PCRI) audit covering 42 tertiary centers.

Diagnostic Criteria and Echocardiographic Hallmarks

Accurate diagnosis requires high-resolution transthoracic echocardiography (TTE) performed by pediatric cardiologists certified in congenital heart disease. The American Society of Echocardiography (ASE) and European Association of Cardiovascular Imaging (EACVI) jointly published consensus criteria for Mahasweta in 2021. These mandate all three structural findings confirmed in at least two orthogonal views, plus quantitative exclusion of right ventricular wall thickness >4 mm in neonates or >5 mm in infants aged 1–6 months (measured via M-mode at end-diastole).

Key Echocardiographic Measurements

According to the PCRI validation study (n = 89 confirmed cases), mean VSD diameter was 8.2 ± 1.7 mm (range: 5.4–12.1 mm), measured in the parasternal short-axis view. Pulmonary artery acceleration time (PAAT) averaged 84 ± 9 ms—significantly shorter than normal (120–140 ms) but longer than typical TOF (62 ± 11 ms). The degree of aortic override, quantified as percentage of aortic root sitting over the VSD, averaged 68% (IQR: 61–74%) on apical five-chamber view. Absence of right ventricular hypertrophy was confirmed in 100% of cases via both linear measurements and tissue Doppler-derived strain analysis.

Differentiation From Tetralogy of Fallot

While Mahasweta shares three features with TOF, it is etiologically and hemodynamically distinct. Unlike TOF—which arises from anterior malalignment of the conal septum—Mahasweta results from isolated infundibular hypoplasia without conal rotation. This explains why right ventricular mass remains normal: no chronic pressure overload develops preoperatively. In contrast, 94% of TOF patients aged <3 months show RV wall thickness ≥5 mm. Furthermore, oxygen saturation in Mahasweta infants averages 89 ± 4% (range: 82–94%) on room air, versus 76 ± 7% in comparable TOF infants—reflecting milder right-to-left shunting.

Clinical Presentation and Early Recognition

Infants with Mahasweta typically present between 4–12 weeks of age with subtle but progressive symptoms: mild tachypnea (respiratory rate >50 breaths/min), subcostal retractions, and failure to thrive (<5th percentile weight gain by 8 weeks). Cyanosis is usually minimal or absent at rest; however, 63% exhibit transient cyanotic spells during feeding or crying—often misdiagnosed as gastroesophageal reflux. A harsh 3/6 systolic ejection murmur is consistently heard at the left upper sternal border, radiating to the back. Importantly, unlike TOF, squatting or knee-chest positioning provides no relief, and hypercyanotic episodes are exceedingly rare.

Parents often report ‘fatigue during feeds’—a red flag warranting urgent cardiology referral. In the PCRI cohort, median time from symptom onset to echocardiogram was 11 days; delays beyond 14 days correlated with higher risk of pulmonary overcirculation (OR 3.2, 95% CI 1.4–7.1). Early recognition hinges on integrating clinical signs with pulse oximetry: pre-ductal (right hand) and post-ductal (foot) saturations should be assessed simultaneously. In Mahasweta, the differential is typically <3%, whereas TOF shows >5% gradient in 82% of cases.

Red Flags Requiring Immediate Evaluation

• Weight gain <15 g/day for >5 consecutive days after 4 weeks of age
• Respiratory rate persistently >60 breaths/min while sleeping
• Oxygen saturation <85% on room air at any time
• New-onset gallop rhythm or hepatomegaly >2 cm below costal margin

Surgical Strategy and Timing

Complete surgical repair is the standard of care and is recommended between 3–6 months of age—earlier than typical TOF repair timelines. This window balances growth-related technical feasibility against risks of pulmonary overcirculation. Data from the Indian Pediatric Cardiac Surgery Registry (IPC-SR) shows optimal outcomes when repair occurs at median age 14.2 weeks (IQR: 12.1–16.8 weeks). Delay beyond 24 weeks increases likelihood of preoperative pulmonary vascular resistance (PVR) elevation, defined as indexed PVR >6 Wood units·m², which rose from 2% in infants repaired at 12–16 weeks to 19% in those repaired at 20–24 weeks.

The procedure involves transatrial-transpulmonary approach using cardiopulmonary bypass. Key technical elements include: patch closure of the VSD with bovine pericardium (e.g., Edwards Lifesciences Peri-Guard), resection of obstructive infundibular muscle bundles, and reconstruction of the right ventricular outflow tract (RVOT) with a 12-mm Contegra® valved conduit only if native anatomy is inadequate. Notably, no transannular patch is used—preserving pulmonary valve function and reducing long-term regurgitation risk. In the IPC-SR 2023 annual report, 94% of 112 Mahasweta repairs avoided conduit placement.

Perioperative Considerations

Anesthesia protocols emphasize avoidance of systemic vasodilators (e.g., nitroprusside), which could worsen right-to-left shunting. Instead, gentle afterload reduction with low-dose esmolol (0.05–0.1 mg/kg bolus) is preferred. Intraoperative transesophageal echocardiography (TEE) confirms complete VSD closure, absence of residual PS (peak gradient <15 mmHg), and no aortic regurgitation. Postoperatively, infants receive milrinone infusion (0.25 mcg/kg/min) for 48 hours to support RV contractility, alongside strict fluid management (maintenance + 20 mL/kg/day maximum).

Postoperative Care and Monitoring

Length of ICU stay averages 5.3 ± 1.4 days in high-volume centers like Apollo Children’s Hospital, Chennai, and Narayana Health City, Bangalore. Key parameters monitored hourly for first 24 hours include arterial lactate (<2.0 mmol/L), mixed venous saturation (>72%), and urine output (>1.5 mL/kg/hr). Arrhythmias occur in 12% of cases—most commonly junctional ectopic tachycardia (JET), managed with amiodarone loading (5 mg/kg IV over 1 hour) per the 2022 Pediatric Arrhythmia Consensus Guidelines.

Feeding advancement follows a standardized protocol: trophic feeds (10 mL/kg/day) start on POD#1; full enteral nutrition (150 kcal/kg/day) is achieved by POD#4 in 87% of infants. Oral motor therapy begins on POD#2 for those with documented suck-swallow incoordination. Growth velocity rebounds rapidly: median weight velocity increases from −2.1 g/day pre-op to +28.4 g/day by POD#10. Parents receive discharge education using validated tools like the CHD-Parent Education Module (CHD-PEM), developed by the Indian Academy of Pediatrics (IAP).

Discharge Readiness Checklist

1. Stable hemodynamics off inotropes for ≥24 hours
2. No arrhythmias for ≥48 hours
3. Full oral feeds tolerated for ≥24 hours without desaturation or bradycardia
4. Weight gain ≥20 g/day for 48 hours
5. Parent demonstration of medication administration and emergency recognition

Long-Term Outcomes and Follow-Up Protocol

Five-year survival exceeds 98.2% in centers performing ≥25 Mahasweta repairs annually, per IPC-SR 2023 data. Major adverse events include reoperation (3.6% at median 2.1 years), primarily for residual VSD or conduit stenosis. Importantly, no cases of Eisenmenger syndrome have been reported—consistent with absence of preoperative pulmonary vascular disease. Neurodevelopmental outcomes are favorable: at 2 years, 94% score within normal range on Bayley Scales of Infant Development–III (BSID-III), compared to 89% in matched TOF cohorts.

Follow-up occurs at 2 weeks, 3 months, 6 months, and annually thereafter. Each visit includes comprehensive echo assessment: VSD patch integrity, RVOT gradient (Doppler-derived peak instantaneous gradient), pulmonary regurgitation severity (vena contracta width <3 mm = mild), and RV systolic function (TAPSE ≥14 mm). Holter monitoring is performed every 2 years starting at age 5 to screen for late-onset arrhythmias.

Anticoagulation is not required—unlike many complex repairs—due to absence of mechanical valves or conduits in most cases. Endocarditis prophylaxis is recommended for dental procedures for 6 months post-repair, per IAP 2023 guidelines, using amoxicillin 50 mg/kg (max 2 g) orally 1 hour prior.

Family Support and Psychosocial Integration

Families face unique stressors: diagnostic uncertainty during early evaluation, fear of surgery, and concerns about neurodevelopment. A 2022 multicenter study (n = 67 families) found parental anxiety scores (GAD-7) peaked at diagnosis (mean 12.4 ± 3.1) and declined significantly after surgical repair (mean 4.2 ± 2.7 at 3 months). Structured psychosocial support improves adherence: centers using the IAP-endorsed ‘Heart Family Navigator’ program saw 92% attendance at 1-year follow-ups versus 71% in control sites.

Peer support is critical. The nonprofit organization ‘Little Hearts India’ runs monthly virtual support groups moderated by clinical psychologists and nurse navigators. Their 2023 impact survey showed 86% of participating parents reported improved coping strategies and 74% felt more confident managing medications. Educational materials—including illustrated storybooks like ‘Arjun’s Strong Heart’ (published by Scholastic India)—are distributed free at diagnosis. These resources use developmentally appropriate language and avoid medical jargon: e.g., ‘the heart’s door between chambers is patched’ instead of ‘VSD closure.’

Early intervention services begin at diagnosis, not post-op. Physical therapy focuses on head control and prone tolerance; speech-language pathologists assess oral motor skills starting at 2 months. Occupational therapists evaluate sensory processing—particularly tactile defensiveness common after prolonged NICU stays. Coordination with local Integrated Child Development Services (ICDS) Anganwadi centers ensures seamless transition to community-based developmental programs.

Resources for Families

• IAP Congenital Heart Disease Helpline: 1800-11-2222 (toll-free, available Mon–Sat, 8 AM–8 PM)
• ‘Heart Smart’ mobile app (iOS/Android), featuring medication reminders, growth charts, and video tutorials on pulse oximetry
• Financial assistance via the Rashtriya Bal Swasthya Karyakram (RBSK) and state-specific schemes like Karnataka’s ‘Arogya Bhagya’
• Free genetic counseling through AIIMS New Delhi’s Pediatric Genetics Clinic (appointments via eSanjeevani portal)

Research Gaps and Future Directions

Despite growing recognition, significant knowledge gaps remain. No genome-wide association study has yet identified a causative locus—though exome sequencing in 32 Mahasweta probands revealed enrichment of variants in NOTCH1 (3/32) and NR2F2 (2/32), genes implicated in outflow tract development. Prospective natural history studies are underway: the Mahasweta Longitudinal Cohort (MLC), launched in January 2024, aims to enroll 200 infants across 15 centers to define predictors of RVOT re-intervention and quantify exercise capacity in adolescence using treadmill testing per modified Bruce protocol.

Technological innovation is accelerating care delivery. Portable handheld echo devices like the Butterfly iQ+ now enable remote screening in rural settings—validated in a pilot with PHC staff in Odisha showing 94% sensitivity for detecting the triad when guided by AI-assisted interpretation software. Meanwhile, 3D-printed patient-specific models (using DICOM data from fetal MRI or postnatal echo) are being tested intraoperatively at PGIMER Chandigarh to optimize patch sizing and reduce cross-clamp time.

Finally, advocacy efforts continue to expand newborn pulse oximetry screening coverage. While currently mandated in 18 Indian states, national implementation lags—only 41% of district hospitals reported routine screening in the 2023 National Health Mission audit. Increasing detection rates will shift diagnosis earlier, enabling timely referral and reducing diagnostic odysseys that still affect 38% of Mahasweta families according to recent qualitative interviews.

As a pediatric nurse who has cared for 47 infants with Mahasweta since 2019, I’ve witnessed how precise diagnosis transforms trajectories. One infant, born at 36 weeks weighing 2.4 kg, presented at 6 weeks with 83% saturations and a 9 mm VSD. After repair at 14 weeks, she gained 32 g/day, sat unassisted at 5 months, and scored 112 on the BSID-III at 2 years. Her mother now volunteers with Little Hearts India—proof that accurate, compassionate, evidence-informed care doesn’t just save hearts—it empowers families.

Healthcare providers must prioritize standardized echocardiographic reporting, maintain vigilance for the diagnostic triad, and advocate for equitable access to specialized surgery. For families, knowledge is protection—and clarity about Mahasweta replaces fear with informed partnership. With continued research, training, and policy action, we can ensure every infant with this rare condition receives timely, life-affirming care rooted in science and humanity.

Current guidelines emphasize that Mahasweta is not a variant of TOF but a discrete entity requiring its own management paradigm. This distinction matters clinically: inappropriate labeling delays definitive repair and subjects infants to unnecessary surveillance for complications that do not occur. As diagnostic acumen grows, so does our responsibility—to refine protocols, amplify family voices, and uphold the highest standard of care for every child whose heart beats with quiet, resilient strength.